Check for updates

OPEN ACCESS

EDITED BY Marek Nalos, Nepean Hospital, Australia

REVIEWED BY Arnoldo Santos, University Hospital Fundación Jiménez Díaz, Spain Kaiquan Tan, MOH Holdings, Singapore

*CORRESPONDENCE Xiaolong Xu, ∞ xiaolong_xu3013@126.com Qingquan Liu, ∞ liuqingquan_2003@126.com

RECEIVED 19 February 2024 ACCEPTED 20 May 2024 PUBLISHED 20 June 2024

CITATION

Huang P, Liu F, Hu X, Li B, Xu X and Liu Q (2024), Effect of ultrashort-acting β -blockers on 28day mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a meta-analysis of randomized controlled trials and trial sequential analysis. *Front. Pharmacol.* 15:1380175. doi: 10.3389/fphar.2024.1380175

COPYRIGHT

© 2024 Huang, Liu, Hu, Li, Xu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Effect of ultrashort-acting β-blockers on 28-day mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a meta-analysis of randomized controlled trials and trial sequential analysis

Po Huang¹, Fusheng Liu¹, Xiao Hu¹, Bo Li^{2,3}, Xiaolong Xu^{2,3}* and Qingguan Liu^{2,3}*

¹Beijing Dongfang Hospital, Beijing University of Traditional Chinese Medicine, Beijing, China, ²Beijing Hospital of Traditional Chinese Medicine, Affiliated with Capital Medical University, Beijing, China, ³Beijing Institute of Traditional Chinese Medicine, Beijing, China

Purpose: This meta-analysis aims to identify whether patients with sepsis who have persistent tachycardia despite initial resuscitation can benefit from ultrashort-acting β -blockers.

Materials and methods: Relevant studies from MEDLINE, the Cochrane Library, and Embase were searched by two independent investigators. RevMan version 5.3 (Cochrane Collaboration) was used for statistical analysis.

Results: A total of 10 studies were identified and incorporated into the metaanalysis. The results showed that the administration of ultrashort-acting β blockers (esmolol/landiolol) in patients with sepsis with persistent tachycardia despite initial resuscitation was significantly associated with a lower 28-day mortality rate (risk ratio [RR], 0.73; 95% confidence interval [CI], 0.57–0.93; and *p*°0.01). Subgroup analysis showed that the administration of esmolol in patients with sepsis was significantly associated with a lower 28-day mortality rate (RR, 0.68; 95% CI, 0.55–0.84; and *p*°0.001), while there was no significant difference between the landiolol and control groups (RR, 0.98; 95% CI, 0.41–2.34; and *p* = 0.96). No significant differences between the two groups were found in 90-day mortality, mean arterial pressure (MAP), lactate (Lac) level, cardiac index (CI), and troponin I (TnI) at 24 h after enrollment.

Conclusion: The meta-analysis indicated that the use of esmolol in patients with persistent tachycardia, despite initial resuscitation, was linked to a notable reduction in 28-day mortality rates. Therefore, this study advocates for the consideration of esmolol in the treatment of sepsis in cases where tachycardia persists despite initial resuscitation.

KEYWORDS

ultrashort-acting β-blockers, mortality, sepsis, tachycardia, meta-analysis

10.3389/fphar.2024.1380175

Introduction

Currently, sepsis remains a life-threatening condition in emergency and critical care medicine due to its dysregulated inflammatory response to infection (Singer M et al., 2016; Hollenberg and Steven, 2023). Despite early active bundle treatment, mortality rates remain high (Li et al., 2022; Weng et al., 2023). Traditionally, β -blockers have been viewed as having negative effects on myocardial inotropy and the heart rate, potentially impacting hemodynamics and reducing cardiac output in sepsis patients. This has led to debates regarding the use of β-blockers in this patient population. However, recent research studies (Parker et al., 1987; Kuipers et al., 2014; Walkey et al., 2014; Hayase et al., 2016) have indicated that tachycardia significantly increases sepsis mortality, and a reduction in the heart rate (within 24 h) can lead to improved outcomes (Parker et al., 1987). As a result, there is a growing interest in studying the effectiveness of βblockers in managing septic tachycardia (Walkey et al., 2014; Yang et al., 2023).

Previous research has demonstrated the effectiveness of esmolol in achieving target heart rates and reducing the 28day mortality of septic patients with tachycardia (Morelli et al., 2013). Subsequent meta-analyses have further supported the benefits of esmolol in sepsis/septic shock patients (Liu et al., 2018; Huang et al., 2021). The potential therapeutic advantages of landiolol, a highly selective $\beta 1$ receptor blocker, in septic patients with tachycardia warrant additional investigation (Lall et al., 2021; Gangl et al., 2022). A recent multicenter clinical trial (J-Land 3S) revealed that although landiolol did not decrease the 28-day mortality of septic patients, it did significantly lower their heart rates, allowing more patients to reach the desired 60-94 beats/min range within 24 h without an increase in adverse events (Kakihana et al., 2020). However, another multicenter clinical trial (Whitehouse et al., 2023) found that administering landiolol to sepsis patients did not decrease the SOFA score but increased the 28-day mortality and adverse event rates. Consequently, the use of landiolol in sepsis patients is not recommended. Therefore, it is crucial to systematically assess the efficacy of esmolol and landiolol in sepsis. Hasegawa et al. (2021) addressed this, but they evaluated esmolol and landiolol together without a separate analysis of landiolol.

A significant concern about the use of β 1-blockers for sepsis is the potential decrease in cardiac output, which may result in hypotension. Therefore, the treatment of tachycardia in septic shock remains a topic of controversy. There is ongoing debate regarding the suitability of both esmolol and landiolol for patients with sepsis and tachycardia, given that they are both β 1-blockers. This study aims to evaluate esmolol and landiolol as distinct interventions to determine their impact on the prognosis of sepsis patients with tachycardia.

Materials and methods

This study adhered to the recommendations and checklist outlined in the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement (Moher et al., 2009). The protocol was registered in PROSPERO (www.crd.york.ac.uk) on 15 January 2024 (Registration ID: CRD42024497520).

Search strategy

The databases PubMed, Embase, and the Cochrane Library were searched from their inception to 3 January 2024 using keywords such as esmolol, landiolol, sepsis, and randomized controlled trial (RCT). The theme of word search for tachycardia was initially considered in our search, resulting in 44 items. However, we were concerned that this search strategy might be too narrow and could potentially overlook important clinical trials. To broaden the search scope, we implemented the current search method, ultimately yielding 122 items, as shown in Supplementary Figure S1.

Eligibility criteria of original studies and study selection

In this study, the inclusion criteria consisted of patients aged 18 years or older with sepsis exhibiting persistent tachycardia despite initial resuscitation (after 24 h of hemodynamic optimization aimed at establishing an adequate circulating blood volume, a mixed venous oxygen saturation higher than 65%, and a mean arterial pressure [MAP] of 65 mmHg or higher, while their heart rate persisted at 95/min or higher), meeting sepsis-1, sepsis-2, or sepsis-3 definitions. The interventions included IV esmolol/ landiolol, with the control being a placebo or no intervention. Primary outcomes focused on 28-day mortality, while secondary outcomes included 90-day mortality, heart rate (HR), MAP at 24 h post-enrollment treatment, norepinephrine (NE) dose, lactate level, cardiac index (CI), stroke volume index (SVI), troponin I (TnI), length of stay (LOS) in the ICU, and adverse events. The study design was an RCT, with abstracts and titles screened by two independent reviewers (HX and HP), and any disagreements were resolved through discussion to reach a consensus. The authors of the included trials were contacted for clarification when needed.

Data extraction

A pre-defined data extraction form was used in this study, with two reviewers (HX and HP) independently extracting information such as the first author, published year, sample size, intervention, control, and outcomes from the selected trials. Any discrepancies between the two reviewers were resolved through discussion with a third reviewer until a consensus was reached.

Bias risk in individual trials

The methodological quality of the studies was evaluated by independent reviewers (HX and HP) to assess the risk of bias. Any disagreements were resolved through further discussions. In cases where reaching a conclusion was challenging, a third reviewer (XXL) reviewed the entire article and participated in the discussion. The risk of bias in each trial was assessed using the Cochrane Collaboration tool for evaluating bias in randomized trials.



Statistical analysis

Statistical analysis was conducted using RevMan version 5.3 from the Cochrane Collaboration. The Cochrane Handbook of Systematic Reviews guided the selection of risk ratios (RRs) and 95% confidence intervals (CIs) for dichotomous outcome evaluation, while the mean difference and its 95% CI were used for continuous outcomes. Between-study heterogeneity was assessed using an I² test, where 25% or lower indicated low heterogeneity, 50% indicated moderate heterogeneity, and 75% indicated high heterogeneity. The fixed-effects model was used in cases of no or low heterogeneity, and pooled RRs were calculated using the Mantel-Haenszel method. Publication bias was investigated if there were more than 10 studies for a specific outcome. A significance level of p < 0.05 was applied. Trial sequential analysis (TSA) was conducted for subgroup analysis of esmolol using TSA viewer version 0.9 Beta (http://www.ctu.dk/tsa/). The parameters used were as follows: the control group had a mortality rate of 50%, the experimental group had a mortality rate of 35%, a two-sided $\alpha = 0$. 05 for the difference test, and $1-\beta = 0.8$.

Results

Description and risk of bias of included studies

A total of 213 records were identified using the search strategy, with 89 potentially eligible records obtained after

removing duplicates. Following the screening of titles and abstracts, 57 studies were excluded, resulting in the inclusion of 10 studies (Morelli et al., 2013; Yang et al., 2014; Liu et al., 2015; Wang et al., 2015; Wang et al., 2017; Liu et al., 2019; Kakihana et al., 2020; Cocchi et al., 2022; Wang et al., 2023; Whitehouse et al., 2023) involving 881 participants (Figure 1). The characteristics of these included studies are given in Table 1. The risk of bias in these studies was assessed using the Cochrane Collaboration tool, with the results given in Supplementary Figure S2. All 10 studies (Morelli et al., 2013; Yang et al., 2014; Liu et al., 2015; Wang et al., 2015; Wang et al., 2017; Liu et al., 2019; Kakihana et al., 2020; Cocchi et al., 2022; Wang et al., 2023; Whitehouse et al., 2023) were deemed to have low risk in terms of random sequence generation, incomplete outcome data, and selective reporting. Five studies (Liu et al., 2019; Kakihana et al., 2020; Cocchi et al., 2022; Wang et al., 2023; Whitehouse et al., 2023) were considered to have a low risk for allocation concealment, while this could not be assessed in the other five studies (Morelli et al., 2013; Yang et al., 2014; Liu et al., 2015; Wang et al., 2015; Wang et al., 2017) due to insufficient information. One study (Wang et al., 2017) was rated as low risk, while five (Morelli et al., 2013; Wang et al., 2015; Liu et al., 2019; Kakihana et al., 2020; Cocchi et al., 2022) were rated as high risk for blinding of participants and personnel. Similarly, two studies (Kakihana et al., 2020; Cocchi et al., 2022) were deemed high risk and four (Morelli et al., 2013; Wang et al., 2015; Liu et al., 2019; Whitehouse et al., 2023) were deemed low risk for blinding of outcome

TABLE 1 C	haracteristics	of	the	included	studies.

Study	Country	No. of	Intervent	ion	Setting	Study	Outcomes	Administration of esmolol/	
		participants	Experimental group	Control group		period		landiolol	
Morelli et al. (2013)	Italy	154	Esmolol	None	Single center	November 2010 to July 2012	HR, 28-day mortality, hemodynamic markers, norepinephrine dose, and adverse events	Administration of esmolol: initiated after randomization that was performed after resuscitation with fluid and vasopressors for 24 h. Initial dose of esmolol: initiated at 25 mg/h	
								Titration or tapering: by ≥ 50 mg/h, slowly every 20 min, to reach HR between 80 and 94 beats/ min within 12 h. Duration of administration: esmolol was continued until ICU discharge or death. The permitted maximum dose was 2,000 mg/h	
Yang et al. (2014)	China	41	Esmolol	None	Single center	January 2012 to January 2014	Hemodynamic parameters including MAP, CVP, HR, CO, CI, SVI, and SVRI and tissue oxygenation parameters including ScvO ₂ and Lac	Administration of esmolol: initiated after randomization that was performed after 6 h resuscitation with fluid and vasopressors. Initial dose of esmolol: 0.05 mg/kg/min. Titration of tapering: adjusted to achieve HR of <100 beats/min in 2 h. Duration of administration: not reported	
Liu et al. (2015)	China	48	Esmolol	None	Single center	September 2013 to September 2014	28-day mortality, LOS in ICU, hemodynamic parameters such as HR, MAP, CVP, CI, SVI, and SVRI and tissue oxygen metabolism markers	Administration of esmolol: initiated after randomization that was performed after resuscitation with fluid and vasopressors for 6 h. Initial dose of esmolol: initiated at 0.05 mg/kg/ min. Titration or tapering: adjusted to reach HR of <100 beats/min within 24 h. The permitted maximum dose was not specified. Duration of administration: not reported	
Wang et al. (2015)	China	60	Esmolol + milrinone	None	Single center	June 2013 to June 2014	28-day survival rate, HR, hemodynamic and organ function variables, myocardial injury markers, serum pro- inflammatory markers, norepinephrine dose, and adverse events	Administration of esmolol: not reported. Initial dose of esmolol: not reported Titration or tapering: not reported. Duration of administration: not reported	
Wang et al. (2017)	China	60	Esmolol	None	Single center	August 2014 to October 2016	28-day mortality, cardiac output, MAP, CI, SVI, inflammatory markers, hemodynamics, and organ function markers	Administration of esmolol: initiated after randomization that was performed after resuscitation with fluid and vasopressors for 24 h. Initial dose of esmolol: initiated at 3 mg/kg/min.	

(Continued on following page)

TABLE 1 (Continued) Characteristics of the included studies.

Study	Country	No. of	Intervent	ion	Setting	Study	Outcomes	Administration of
		participants	Experimental group	Control group		period		landiolol
								Titration or tapering: by 50 mg/h every 5 min to reach HR of <95 beats/ min within 4 h. The permitted maximum dose was 12 mg/kg/min. Duration of administration: esmolol was continued for 24 h
Liu et al. (2019)	China	100	Esmolol	None	Single center	June 2016 to August 2017	28-day mortality; 7- , 60-, and 90-day mortalities; HR; Lac; inflammatory marker; and length of hospital stay	Administration of esmolol: initiated after randomization that was performed after being resuscitated with fluid and vasopressors for 24 h. Initial dose of esmolol: initiated at 25 mg/h. Titration or tapering: by 50 mg/h every 20 min to reach HR between 80 and 100 beats/min within 12 h. The permitted maximum dose was 0.3 mg/kg/min. Duration of administration: esmolol was continued until day 7, ICU discharge, or death
Kakihana et al. (2020)	Japan	151	Landiolol	None	Multicenter	January 2018 to April 2019	28-day mortality, HR, norepinephrine dosages, and adverse events	Administration of landiolol: landiolol was initiated within 2 h after randomization that was conducted after being resuscitated with fluid and vasopressors. Mean time ± SD from entering ICU to randomization was 15.8 ± 13.4 h in the landiolol group and 13.5 12.6 h in the control group. Initial dose of landiolol: initiated at 1 mg/kg/min. Titration or tapering: by 1 mg/kg/min generally every 15–20 min, until the HR decreased to <95 beats/ min. Duration of administration: landiolol was continued for at least 96 h after randomization. It was optional between 96 and 168 h after randomization
Cocchi et al. (2022)	America	42	Esmolol	None	Two centers	January 2015 to December 2019	Inflammatory biomarkers and oxygen consumption (VO ₂) and norepinephrine equivalent dose	Esmolol was titrated to a heart rate of 80–94 per min, starting at 50 mcg/kg/min and subsequently increasing every 20 min in increments of 50 mcg/kg/ min (or slower at the discretion of the clinical team) until the target was achieved. The maximum allowed dose was 300 mcg/kg/min. Esmolol was continued for 24 h

(Continued on following page)

Study	Country No. of		Intervent	ion	Setting	Study	Outcomes	Administration of esmolol/
		participants	Experimental group	Control group		penod		landiolol
Whitehouse et al. (2023)	United Kingdom	126	Landiolol	None	Multicenter	19 April 2018 to 15 December 2021	SOFA score, 28-day mortality, 90-day mortality, length of hospital stay, LOS in ICU, HR, Lac, MAP, and adverse events	Continuous intravenous infusion of landiolol was started at 1.0 mcg/kg/min, increasing every 15 min by a step change of 1.0 mcg/kg/min to reach the target HR of 80–94 bpm with the expectation that this should be within 6 h. While the patient was receiving vasopressor agents (norepinephrine and/or vasopressin), the landiolol infusion was adjusted by step changes of 1.0 mcg/kg/min to maintain the target HR. It was recommended that the landiolol infusion be stopped for at least 12 h before the patient was discharged from the ICU
Wang et al. (2023)	China	100	Esmolol	None	Single center	March 2020 to September 2021	LVEF, HR, 28-day and 90-day mortality, and adverse events	Administration of esmolol: with a loading dose of 0.5 mg/kg, followed by continuous intravenous pumping at 0.05 mg/kg/ min for maintenance. If the effect is not favorable after 4 min, administer the loading dose again and increase the maintenance dose by 0.05 mg/kg/min. The maximum maintenance dose can be increased to 0.2 mg/kg/min. Duration of administration: not reported

TABLE 1 (Continued) Characteristics of the included studies.



1.2.1 Esmolol	p Events	Total Even	ts Total	Weigh	t M-H, F	Random, 95% Cl	M-H, Random, 9	5% CI	
Liu H 2019 Wang J 2023	33 29	50 3 50 3	36 50 36 50	39.3% 36.9%	5 (5 (0.92 [0.70, 1.19] 0.81 [0.60, 1.08]	-		
Subtotal (95% CI) Total events	62	100 7	100 2	76.2%	6 0	0.87 [0.71, 1.05]	•		
Heterogeneity: Tau Test for overall effe	² = 0.00; Chi ² = 0.4 ect: Z = 1.45 (P = 0.	2, df = 1 (P = 0 15)	0.52); l ² =	0%					90-d mortality
1.2.2 Landiolol Whitehouse 2023	27	62 1	8 63	23.8%		1.52 [0.94, 2.47]	-		50 a moranty
Subtotal (95% CI) Total events	27	62 1	63 8	23.8%	6 1	.52 [0.94, 2.47]	•		
Heterogeneity: Not Test for overall effe	applicable ect: Z = 1.71 (P = 0.	09)							
Total (95% CI)	89	162 c	163	100.0%	6 0	0.99 [0.72, 1.35]	+		
Heterogeneity: Tau Test for overall effe	² = 0.05; Chi ² = 5.3 ect: Z = 0.09 (P = 0.	5, df = 2 (P = 0 93)	0.07); l² =	63%		+ 0.0	05 0.1 1	10 200	
Test for subaroup of	differences: Chi ² = 4	1.55. df = 1 (P =	= 0.03). I ^s	² = 78.0%		Fa	vouis Esmolo/Landiolor Pavo		
Study or Subgroup	Esmolol/Land Mean SD	liolol C Total Mean	Control SD 1	Fotal W	Std. eight IV	Mean Difference /. Random. 95% Cl	Std. Mean Diffe	erence 95% Cl	
Liu H 2019	106 17 84.4 3.5	50 114 24 111 2	17 7 2	50 1 24	1.6%	-0.47 [-0.86, -0.07]			
Morelli 2013 Wang J 2023	84.9 6.4 84.86 7.03	77 108.6 50 118.1	15.2 13.19	77 1 50 1	1.6% 1.1%	-2.02 [-2.41, -1.63] -3.12 [-3.71, -2.53]	_		
Wang S 2017 Wang Z 2015	90.9 14.8 84 12	30 97.7 30 115	15.3 19	30 1 30 1	1.3% 1.0%	-0.45 [-0.96, 0.07] -1.93 [-2.54, -1.31]			
Yang 2014 Subtotal (95% CI)	89 8	21 113 282	14	20 1 281 7	0.6% 6.6%	-2.08 [-2.85, -1.30] -2.04 [-2.94, -1.13]	→		Heart rate at 24h, beats/minute
Test for overall effect	ct: Z = 4.42 (P < 0.00	55, df = 6 (P < 0 001)	1.00001);1	1* = 95%					
1.3.2 Landiolol Kakihana 2020	94.7 18.2	75 99.5	19	75 1	1.7%	-0.26 [-0.58, 0.06]	-		
Whitehouse 2023 Subtotal (95% CI)	92.4 10.4	63 98.6 138	12.2	63 1 138 2	1.7% 3.4%	-0.54 [-0.90, -0.19] -0.39 [-0.67, -0.11]	•		
Heterogeneity: Tau ² Test for overall effect	= 0.01; Chi² = 1.38, ct: Z = 2.72 (P = 0.00	df = 1 (P = 0.24 06)	4); I² = 27	%					
Total (95% CI) Heterogeneity: Tau ²	= 1.18; Chi ² = 169.6	420 58. df = 8 (P < 0	.00001):	419 10 ² = 95%	0.0%	-1.65 [-2.38, -0.91]	•	t	
Test for overall effect Test for subgroup di	t: Z = 4.39 (P < 0.00 fferences: Chi ² = 11	001) .65. df = 1 (P =	0.0006).	l² = 91.4%	6		10 -5 0 Favours Esmolol/Landiolol Fav	5 10 vours Control	
	Esmolol/Lan	diolol	Control		S	td. Mean Difference	Std Mean	Difference	
Study or Subgrou	p Mean SD	Total Mean	n SD	Total	Weight	IV, Random, 95% (IV, Rando	pm. 95% Cl	
Study or Subgrou 1.4.1 Esmolol Liu X 2015	p Mean SD 70.7 1.8	<u>Total Mea</u> 24 71.0	n SD 6 1.6	Total 24	Weight 8.2%	IV. Random, 95% (IV, Rando	om, 95% Cl	_
Study or Subgrou 1.4.1 Esmolol Liu X 2015 Morelli 2013 Wang J 2023	p Mean SD 70.7 1.8 71.8 4.3 83.2 13.19	24 71.0 77 71.0 50 81.11	n SD 6 1.6 9 4.9 2 12.54	24 77 50	8.2% 17.6% 13.9%	IV. Random, 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 0.16 [-0.23, 0.55		om, 95% Cl	_
Study or Subgrou 1.4.1 Esmolol Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Vars 2014	p Mean SD 70.7 1.8 71.8 4.3 83.2 13.19 78.3 8.5 71 22 72 25	Total Mean 24 71.0 77 71.1 50 81.1 30 82.3 30 62	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 21	Total 24 77 50 30 30	8.2% 17.6% 13.9% 9.8% 10.0%	IV. Random, 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 0.09 [-0.41, 0.60	21 IV. Rande	95% Cl	_
<u>Study or Subgrou</u> 1.4.1 Esmolol Liu X 2015 Morelli 2013 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (95% CI) Heterogeneity: Tau	p Mean SD 70.7 1.8 71.8 4.3 83.2 13.19 78.3 8.5 71 22 77 8.5 2 = 0.01 Chi ² = 6.14	Total Mean 24 71.1 50 81.1 30 82.2 30 63 21 7 232 6 df = 5 (P = 0	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29): I ² = 1	Total 24 77 50 30 30 20 231	8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0%	IV. Random. 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 0.09 [-0.41, 0.60 -0.25 [-0.86, 0.37 -0.10 [-0.31, 0.11]	21 IV. Rande		_
Study or Subgrou 1.4.1 Esmolol Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (95% Cl) Heterogeneity: Tau Test for overall effe	p Mean SD 70.7 1.8 4.3 71.8 4.3 83.2 13.19 78.3 8.5 71 22 77 8.5 2 = 0.01; Chi ² = 6.16 ct; Z = 0.95 (P = 0.3)	Total Mean 77 71.1 50 81.11 30 82. 30 68 21 79 232 3, df = 5 (P = 0. 34)	n <u>SD</u> 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); l ² = 1	Total 24 77 50 30 20 231 19%	8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0%	IV. Random. 95% 6 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 0.09 [-0.41, 0.60 -0.25 [-0.86, 0.37 -0.10 [-0.31, 0.11]	21 IV. Rands	Unreferee Science 	 Mean Arterial Pressure at 24h, mmHg
Study or Subgrou 1.4.1 Esmolo Liu X 2015 Morelli 2013 Wang J 2023 Wang Z 2017 Wang Z 2017 Wang Z 2017 Yang 2014 Subtotal (95% Cl) Heterogeneity: Tau Test for overall effe 1.4.2 Landiolol Kakihana 2020	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Total Mean Total Mean 77 71.1 50 81.1: 30 82. 30 6: 21 7: 232 6; df = 5 (P = 0. 34) 75 81.3	n <u>SD</u> 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); I ² = ⁴ 8 15.4	<u>Total</u> 24 77 50 30 20 231 19% 75	8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3%	U. Random. 95% 0 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 0.09 [-0.41, 0.60 -0.25 [-0.66, 0.37 -0.10 [-0.31, 0.11]			— Mean Arterial Pressure at 24h, mmHg
Study or Subgrou 1.4.1 Esmolol Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (95% CI) Heterogeneity: Tau Test for overall effe Kakihana 2020 Whitehouse 2023 Subtotal (95% CI)	p Mean SD 70.7 1.8 71.8 4.3 83.2 13.1 78.3 8.5 71 22 77 8.5 2 ^a = 0.01; Chi ² = 6.1(ct; Z = 0.95 (P = 0.3 84.1 14.4 73.2 7.6	Total Mean 24 71.1 50 81.1 30 82. 30 62 21 7 232 3, df = 5 (P = 0. 34) 75 81.1 63 71 138	n <u>SD</u> 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); ² = ⁻ 8 15.4 6 6.5	Total 24 77 50 30 20 231 19% 75 63 138	Weight 8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0%	W. Random. 35% 4 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.22 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 0.08 [-0.41, 0.60 -0.25 [-0.66, 0.37 -0.10 [-0.31, 0.11] 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42			 Mean Arterial Pressure at 24h, mmHg
Study or Subgroup 14.1 Esmoloid Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (65% CI) Heterogeneity. Tau Test for overall effe 1.4.2 Landioloi Kakihana 2020 Whitehouse 2023 Subtotal (65% CI) Heterogeneity. Tau Test for overall effe	p Mean SD 70.7 1.8 71.8 43.3 83.2 13.19 78.3 8.5 71 22 77 8.5 71 22 77 8.5 71 22 77 8.5 72 0.01; Chi² = 6.11 6.14 73.2 84.1 14.4 73.2 7.6 73.2 7.6 7.6 7.7 84.1 14.4 73.2 7.6 72 0.12; Chi² = 5.00 6.12 7.6	Total Mean Total	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); $ ^2 = 2$ 8 15.4 6 6.5 02); $ ^2 = 8$	Total 24 77 50 30 20 231 19% 75 63 138 80%	8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0%	IV. Random. 35% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.04, 0.20 -0.16 [-0.23, 0.55 -0.41 [-0.82, 0.10 -0.25 [-0.46, 0.37 -0.16 [-0.31, 0.11 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42]	21 W. Rando		— Mean Arterial Pressure at 24h, mmHg
Study or Subgroup 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Yang 2014 Subtotal (95% CI) Heterogeneity: Tau Test for overall effe 1.4.2 Landioloi Kakihana 2020 Whitehouse 2023 Subtotal (95% CI) Heterogeneity: Tau Test for overall effe Total (95% CI)	p Mean SD 70.7 1.8 71.8 4.3. 83.2 13.19 78.3 8.5 71 22 77 8.5 71 22 77 8.5 ° = 0.01; Chi ² = 6.11 Ct Z = 0.95 (P = 0.2 84.1 14.4 73.2 7.6 ° = 0.12; Chi ² = 5.00 ct Z = 0.42 (P = 0.6	Total Mean 24 71.1 77 71.1 50 81.1 50 81.1 30 62 21 7 232 232 3, df = 5 (P = 0.34) 138 6, df = 1 (P = 0.57) 370 370	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 7.3 29); $ ^2 = 1$ 8 15.4 6 6.5 02); $ ^2 = 8$	Total 24 77 50 30 30 2231 19% 75 63 138 30% 30% 369	Weight 8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0%	W. Random, 35% 6 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.22 0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 -0.25 [-0.86, 0.37 -0.10 [-0.31, 0.11 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.30, 0.08	2 VV. Rando		 Mean Arterial Pressure at 24h, mmHg
Study or Subgrou 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe 14.2 Landioloi Kakihana 2020 Whitehouse 2023 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Tau Test for overall effe	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	total Mean Total M	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); $ ^2 = 1$ 8 15.4 6 6.5 02); $ ^2 = 8$ 0.13 ; $ ^2 = 1$	Total 24 77 50 30 20 231 19% 75 63 138 80% 369 • 38% = 0%	Weight 8.2% 17.6% 13.9% 9.8% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0%	W. Random, 95% of -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11] 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.30, 0.08]	2 V. Rands	merence m. 55% Cl	Mean Arterial Pressure at 24h, mmHg
Study or Subgroup 14.1 Esmoloid Liu X 2015 Morelli 2013 Wang S 2017 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (95% CI) Heterogeneity: Tau Test for overall effe 1.4.2 Landioloi Kakinana 2020 Whitehouse 2023 Subtotal (95% CI) Heterogeneity: Tau Test for overall effe Total (95% CI) Heterogeneity: Tau Test for overall effe Test for subarout of Study or Subbarout	p Mean SD 70.7 1.8 71.8 4.3 83.2 13.10 77.8 5.5 71 22 77.8.5 71.22 77.8.5 84.1 14.4 73.2 7.6 84.1 14.4 73.2 7.6 95.7 95.	i Total Mean i 24 71.1 50 81.1 i 50 81.1 50 81.2 i 21 70 72.1 72 30 6: 212 72 232 i 6: 37 138 3. df = 5 (P = 0.37) 370 22.2 3. df = 1 (P = 0.37) 370 377 370 22.2 df = 1 (P = 0.37) 370 30.0 df = 1 (P = 0.37) 370 300 0.00.0 df = 1 (P = 0.37) 370 300 0.00 0.1 (P = 1.10) 3.00 370 3.00 3.00 3.00 3.00 370 3.00 3.00 3.00 3.00 370 3.00 3.00 3.00 3.00 3.00 370 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00	n SD 6 1.6 9 4.9 2 12.54 7 12.2 9 21 9 7.3 29); $ ^2 = 1$ 8 15.4 6 6.5 02); $ ^2 = 8$ 0.13); $ ^2 = 8$ 0.96). $ ^2$	Total 24 77 50 30 20 231 19% 75 63 138 80% 369 38% = 0% Total	Weight 8.2% 17.6% 13.9% 9.8% 9.8% 67.0% 67.0% 17.3% 15.7% 33.0% 100.0% St Veight	IV. Random. 95% 6 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.22 -0.16 [-0.23, 0.55 -0.41 [-0.22, 0.10 -0.03 [-0.34, 0.26 -0.25 [-0.48, 0.37 -0.10 [-0.31, 0.11 0.15 [-0.7, 0.47 -0.31 [-0.55, 0.42 -0.11 [-0.55, 0.42 -0.11 [-0.30, 0.08 d. Mean Difference IV. Fixed. 95% C	2 VV. Rand	Dimensional States Classical States Clas	— Mean Arterial Pressure at 24h, mmHg
<u>Study or Subgrou</u> 14.1 Emoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang 2 2015 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Total (95% CI) Heterogeneity: Tau Test for subarou d Test for subarou d Test for subarou d Subtotal (95% CI)	p Mean SD 70.7 1.8 4.3 71.8 4.3 83.2 13.19 78.3 8.5 71 22 77 8.5 71 22 77 8.5 71 22 77 8.5 71 22 78 8.5 71 22 77 8.5 71 22 78 8.5 71 22 84.1 14.4 73.2 7.6 73.2 7.6 5.0 7.7 6.12 C.12 0.42 (P = 0.4 2 = 0.03 Chi² = 5.04 7.6 2 = 0.03 Chi² = 11.1 7.6 2 = 0.03 Chi² = 0.13 P 2.5 SE SE SE SE 0.22 Mean SE 0.15	Total Mean	n SD 6 1.6 9 4.9 2 12.64 4 9 1.9 7 12.2 9 2 12.64 6 1.9 7.3 32 9 2 12.64 6 5 0 9 2.1 9 2.1 1.9 7.3 32 29); l ² = 4 6 6.5 0.2); l ² = 4 6 6.5 0.2); l ² = 4 0.96), l ² 0.96), l ² 0.96), l ² Control n SD 6 0.17 6 0.17 1.0 </td <td>Total 24 77 50 30 231 199% 75 63 138 30% 369 38% 369 38% Total V 22</td> <td>Weight 8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0% 100.0% St Veight 6.2%</td> <td>IV. Random. 95% (f) -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.03 [-0.34, 0.50 -0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.30, 0.08 d. Mean Difference IV. Fixed, 95% (f) 0.44 [-0.19, 1.07]</td> <td>2 IV. Rands</td> <td>Favours Esmolo/Landiolol</td> <td>Mean Arterial Pressure at 24h, mmHg</td>	Total 24 77 50 30 231 199% 75 63 138 30% 369 38% 369 38% Total V 22	Weight 8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 17.3% 15.7% 33.0% 100.0% St Veight 6.2%	IV. Random. 95% (f) -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.03 [-0.34, 0.50 -0.16 [-0.23, 0.55 -0.41 [-0.92, 0.10 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.30, 0.08 d. Mean Difference IV. Fixed, 95% (f) 0.44 [-0.19, 1.07]	2 IV. Rands	Favours Esmolo/Landiolol	Mean Arterial Pressure at 24h, mmHg
-Study or Subgroup 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Kakihana 2020 Whitehouse 2023 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Tau Test for overall effe Tostal (95% CI) Heterogeneity: Tau Test for overall effe Asset or suberour of Study or Subgroup Cocchi 2022 Morelli 2013 Wang J 2023	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	i Total Mean i 24 71.1 50 81.1 i 50 81.1 30 66 i 21 72 232 232 232 3.6 of = 5 (P = 0.3) 34) 75 81.3 5. 6f = 1 (P = 0.37) 70 22.6 of = 7 (P = 0.26) 22.00.0 of = 1 (P = 0.37) 370 22.6 of = 7 (P = 0.00.0 of = 1 (P = 0.37) 370 22.6 of = 7 (P = 0.26) 370 22. 31.8 0.1 of = 1 (P = 0.37) 370 370 370 370 31.8 0.1 of = 1 (P = 0.37) 370	n SD 6 1.6 9 4.9 9 4.9 9 4.1 7 12.2 12.2 12.2 12.2 9 21 12.4 7 12.2 9 21 13.4 14.6 15.4 6 16.5 5 5 16.6 5 5 16.1 11.1	Total 24 77 50 30 30 221 19% 75 63 138 30% 369 38% = 0% 77 50 50	8.2% 17.8% 9.8% 9.8% 10.0% 7.3% 67.0% 17.3% 15.7% 33.0% Veight 6.2% 24.6% 6.0%	IV. Random. 95% fl -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.01 [-0.23, 0.55 -0.11 [-0.22, 0.10 -0.02 [-0.34, 0.20 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 -0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.30, 0.08] d. Mean Difference IV. Fixed, 95% C 0.44 [-0.49, 1.07 -0.17 [-0.46, 0.22]	2 IV. Rands	menerace m. 95% Cl 	Mean Arterial Pressure at 24h, mmHg
Study or Subgroup 14.1 Esmoloid Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang S 2017 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe 14.2 Landioloid Kakinana 2020 Whitehouse 2023 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Test for subcround J.S.1 Esmoloi Cocchi 2022 Morelli 2013 Wang J 2023 Wang J 2023		i Total Mean i 24 71.1 i 50 81.1; i 30 6: j 7 71.3 j 6: 7 j 33 6: j 370 7 22, df = 7 (P = (2: j 370 22, df = 7 (P = (j 18 j 18 j 18 j 18 j 18 j 18 j 0.00. df = 1 (P = 0.00.00) j 18 j 18 j 18 j 30 j 30 j 30 j 30	$\begin{array}{cccc} n & SD \\ 6 & 1.6 \\ 9 & 4.9 \\ 9 & 4.9 \\ 7 & 12.2 \\ 2 & 12.54 \\ 7 & 12.2 \\ 2 & 12.54 \\ 1 & 2 & 12.54 \\ 1 & 2 & 12.54 \\ 2 & 12.54 \\ 1 & 2 & 12.54 \\ 2 & 12.54 \\ 1 & 2 &$	Total 24 77 50 300 20 221 199% 755 63 138 30% 369 369 238% 775 50 777 500 300 177 777 500 30	Weight 8.2% 17.6% 9.8% 9.8% 67.0% 10.0% 7.4% 67.0% 117.3% 15.7% 33.0% 100.0% St Veight 6.2% 6.2% 6.2% 5.3%	IV. Random. 95% (-0.52 [+1.10, 0.06 -0.02 [+0.34, 0.29 -0.02 [+0.34, 0.29 -0.41, 0.60 -0.25 [-0.47, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.55, 0.42 -0.11 [-0.30, 0.08 d. Mean Difference IV. Fixed, 95% (0.44 [-0.19, 107 -0.16 [-0.48, 0.16] -0.17 [-0.56, 0.22] -0.31 [-0.33, 0.08]	2 V. Rands	Inference 1 2 Favours Esmolo/Landiolol Difference 1 25% Cl	— Mean Arterial Pressure at 24h, mmHg -
Study or Subgrou 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (65% CI) Heterogeneity: Tau Test for overall effe 1.4.2 Landioloi Kakihana 2020 Heterogeneity: Tau Test for overall effe Total (95% CI) Heterogeneity: Tau Test for overall effe Test for subarou of Subtotal (95% CI) Heterogeneity: Tau Test for overall effe Test for subarou of Subtotal (95% CI) Heterogeneity: Tau Test for overall effe Test for subarou of Subtotal (95% CI) Heterogeneity: Cavi Heterogeneity: Cavi Subtotal (95% CI) Heterogeneity: Chi Test for overall effe		Total Mean	n SD 6 1.6.9 4.9 9 4.9 2.12.64 2 12.2.2 12.12 9 7.13 2.9 9 7.3 2.9); I* = + 8 15.4 6 0.13); I* = 0.96); I* 4 0.96); I* 7 5 Control n SD 6 0.17 9 0.79 2 0.5 8 0.24 5 5 5 5	Total 24 77 50 300 20 231 138 30% 369 38% = 0% Total V 22 77 50 30 137 369 38% = 0% Total V 22 77 50 30 30 179	Weight 8.2% 17.6% 13.9% 9.8% 7.4% 67.0% 15.7% 33.0% 100.0% St Veight 6.2% 24.6% 16.0% 9.5% 55.3%	IV. Random. 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.22] -0.31 [-0.32, 0.55 -0.41 [-0.32, 0.55 -0.41 [-0.32, 0.15 -0.41 [-0.32, 0.41, 0.60 -0.25 [-0.66, 0.37 -0.10 [-0.31, 0.11 -0.33 [-0.75, -0.04 -0.11 [-0.55, 0.42] -0.11 [-0.56, 0.42] -0.11 [-0.30, 0.08 IV. Fixed, 95% (0.44 [-0.19, 1.07] -0.33 [-0.48, 0.16] -0.31 [-0.48, 0.08] -0.13 [-0.33, 0.08]	2 V. Rands	Difference 0 1 2 Favours Esmolo/Landiolol Difference 0, 95% Cl	— Mean Arterial Pressure at 24h, mmHg
Study or Stubgrou 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang 2 2015 Wang 2 2017 Wang 2 2017 Yang 2014 Subtata (65% CI) Heterogeneity: Tau Test for overall effe 14.2 Landioloi Kakihana 2020 Whitehouse 2023 Subtata (65% CI) Heterogeneity: Tau Test for overall effe Total (95% CI) Heterogeneity: Tau Test for overall effe Test for subarou 1.5.1 Esmoloi Coacchi 2022 Morelli 2013 Wang 2 2015 Subtata (65% Coachi 2020 Morelli 2013 Wang 2 2015 Subtata (65% Coachi 2020 Morelli 2013 Wang 2 2015 Subtata (65% Coachi 2020 Morelli 2013 Wang 2 2015 Subtata (65% Coachi 2015 Morelli 2015 Morelli 2015 Morelli	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	interface Total Mean i 24 71.1 500 81.1 i 500 81.1 30 62 i 30 66 77 71.3 i 30 66 70 81.3 i 63 77 138 73 370 22.2 df = 1 (P = 0.377) 370 370 370 22.4 df = 1 (P = 0.400) 0 Total Mean 0.1 7 77 0 18 0.1 7 77 0 30 0.29); i'' = 20% 24) 24) 24 24 24	N SD 6 1.6. 9 4.9 4.9 2 12.54 4.9 2.1 12.54 9 2.1 9 7.1 9 2.1 9 7.1 9 2.1 9 7.1 9 7.3 9 7.3 9 7.3 9 7.3 9 7.3 9 7.9 9 9 2.1 9 7.1 9 0.7 9 <t< td=""><td>Total 24 77 50 300 201 138 300% 369 369 38% = 0% Total V 22 77 50 30 300% 138 300% 369 300% 369 138 300% 179 75 50 30 179 75</td><td>Weight 8.2% 17.6% 13.9% 9.8% 7.4% 67.0% 15.7% 33.0% 100.0% 15.7% 33.0% 100.0% St 4.6% 9.5% 56.3% 22.8%</td><td>IV. Random. 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.02 [-0.34, 0.29 -0.02 [-0.34, 0.29 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.31 [-0.35, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 0.44 [-0.19, 1.07] -0.15 [-0.48, 0.16] -0.13 [-0.33, 0.08] 0.28 [0.02, 0.02]</td><td>2 IV. Rando</td><td>Firefore model in the second s</td><td> Mean Arterial Pressure at 24h, mmHg Norepinephrine dose at 24h, μg/kg/mi</td></t<>	Total 24 77 50 300 201 138 300% 369 369 38% = 0% Total V 22 77 50 30 300% 138 300% 369 300% 369 138 300% 179 75 50 30 179 75	Weight 8.2% 17.6% 13.9% 9.8% 7.4% 67.0% 15.7% 33.0% 100.0% 15.7% 33.0% 100.0% St 4.6% 9.5% 56.3% 22.8%	IV. Random. 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.02 [-0.34, 0.29 -0.02 [-0.34, 0.29 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.31 [-0.35, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 0.44 [-0.19, 1.07] -0.15 [-0.48, 0.16] -0.13 [-0.33, 0.08] 0.28 [0.02, 0.02]	2 IV. Rando	Firefore model in the second s	 Mean Arterial Pressure at 24h, mmHg Norepinephrine dose at 24h, μg/kg/mi
Study or Subgroup 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang J 2023 Wang Z 2015 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effor Test for test for	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	i Total Mean i 24 71.1 i 50 81.1 i 30 66 i 21 72 232 232 232 i 63 71 i 30 66 j 138 138 i 370 22, df = 7 (P = 0.0 22, df = 7 (P = 0.00, df = 1 (P = 0.00,	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Total 244 27 77 30 30 200 231 199% 369 388% 369 = 0% 22 77 50 338% 20% 369 38% = 0% 22 77 50 300 179 75 63 138 138	Weight 8.2% 17.6% 13.9% 9.8% 10.0% 7.4% 67.0% 15.7% 33.0% 100.0% 15.7% 33.0% 100.0% 57.0% 15.7% 16.7% 57.0% 15.7% 16.7% 15.7% 15.7% 16.7% 15.7% 15.7% 16.7% 15.7% 16.7% 15.7% 15.7% 16.7% 15.7% 16.7% 15.7% 16.7% 15.7% 16.7% 17.3% 16.7% 1	IV. Random. 95% 6 -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.02 [-0.34, 0.26 -0.01 [-0.23, 0.55 -0.11 [-0.22, 0.10 -0.15 [-0.17, 0.47 -0.39 [-0.75, -0.04 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.65, 0.42 -0.11 [-0.48, 0.16 -0.13 [-0.44, 0.68 -0.13 [-0.48, 0.16 -0.13 [-0.48, 0.16 -0.13 [-0.48, 0.18 -0.13 [-0.33, 0.08] 0.33 [0.00, 0.55 0.33 [0.00, 0.55 0.33 [0.00, 0.65 0.33 [0.00, 0.44 0	2 IV. Rands	Professional Control C	Mean Arterial Pressure at 24h, mmHg - - Norepinephrine dose at 24h, μg/kg/mi
Study or Stuberou 14.1 Emoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Tau Test for overall effe Total (85% CI) Heterogeneity: Chi Test for overall effe Subtotal (85% CI) Heterogeneity: Chi Test for overall effe Subtotal (85% CI) Heterogeneity: Chi Test for overall effe 15.1 Esmolol Cocchi 2022 Morelli 2013 Wang J 2023 Wang J 2023 Morelli 2013 Wang J 2023 Wang J 2023		Total Mean	N SD 6 1.6. 9 4.9 9 4.9 9 2.1 12.54 9 2.1 2.9 12.9 9 2.1 9 7.3 3 22 9 2.1 9 7.3 22 9 2.1 9 7.3 23 29 7.3 23 29 2 12.54 6 6.5 0 7 12.0 0 13.1 12 2 0.13); 12 2 0.96 0.17 1 0.96 0.17 1 0.2 0 9 2 0.5 8 0.24 5 0.12 4 0.23 5 0.12 4 0.23 5 0.12 4 0.23 5 0.12 14 0.23 5 0.12 14 0.23 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10	Total 244 277 50 300 200 201 231 199% 369 38% = = 0% Total V 222 77 50 30 179 75 63 138 755 63 138 138	Weight 17.6% 17.6% 17.6% 13.9% 9.8% 9.8% 9.8% 7.4% 67.0% 17.3% 15.7% 15.7% 15.7% 15.7% 15.7% 15.7% 15.7% 15.7% 56.3% 24.6% 16.0% 9.5% 23.8% 19.9%	IV. Random. 95% fl -0.52 [+1.10, 0.06 -0.02 [+0.34, 0.23 -0.01 [+0.32, 0.55 -0.41 [+0.92, 0.10 0.16 [+0.23, 0.55 -0.41 [+0.92, 0.10 -0.25 [+0.86, 0.37 -0.10 [+0.31, 0.11 0.15 [+0.17, 0.47 -0.39 [+0.75, -0.04 -0.11 [+0.85, 0.42 -0.11 [+0.48, 0.48 -0.11 [+0.48, 0.48 -0.14 [+0.49, 1.07 -0.15 [+0.47, 0.48 -0.11 [+0.48, 0.48 -0.13 [+0.40, 0.08 0.44 [+0.19, 1.07 -0.16 [+0.48, 0.46 -0.17 [+0.56, 0.22 -0.33 [-0.40, 0.18] -0.13 [+0.43, 0.08] 0.33 [0.00, 0.65] 0.33 [0.00, 0.65] 0.33 [0.00, 0.65] 0.33 [0.00, 0.65] 0.33 [0.00, 0.65]	2 IV. Rands	menerace m. 95% Cl 	 Mean Arterial Pressure at 24h, mmHg Norepinephrine dose at 24h, μg/kg/mi
Study or Subgroup 14.1 Emoloid Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe 14.2 Landioloid Kakinana 2020 Whitehouse 2023 Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Test for subarous d Subtotal (85% CI) Heterogeneity: Tau Test for voreall effe Test for subarous d Subtotal (85% CI) Heterogeneity: Tau Test for overall effe Test for voreall effe 15.1 Esmolol Cocchi 2022 Wang J 2015 Subtotal (85% CI) Heterogeneity: Chi Test for voreall effe 15.2 Landiolol Kakinana 2020 Whitehouse 2023 Subtotal (85% CI)		Total Mean	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Total 244 277 50 300 200 201 231 199% 369 3699 38% = 0% 775 777 500 300% 369 3699 38% = 0% 777 500 300 3138 3179	Weight 8.2% 17.6% 13.9% 9.8% 7.4% 67.0% 17.3% 15.7% 33.0% 17.3% 15.7% 33.0% 100.0% St 56.3% 100.0%	IV. Random. 95% d -0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29 -0.25 [-0.34, 0.29 -0.25 [-0.34, 0.29 -0.41, 0.60 -0.25 [-0.41, 0.60 -0.25 [-0.46, 0.37 -0.10 [-0.31, 0.11 0.15 [-0.17, 0.47 -0.39 [-0.75, -0.44 -0.11 [-0.50, 0.42 -0.11 [-0.50, 0.42 -0.11 [-0.50, 0.42 -0.11 [-0.50, 0.42 -0.33 [-0.48, 0.16] -0.13 [-0.33, 0.08] 0.33 [0.00, 0.65 0.35 [-0.00, 0.70 0.34 [0.10, 0.57] 0.08 [-0.88, 0.23]	2 V. Rands	Dimensional and the second sec	Mean Arterial Pressure at 24h, mmHg - - Norepinephrine dose at 24h, μg/kg/mi
Study or Subgroup 14.1 Esmoloi Liu X 2015 Morelli 2013 Wang J 2023 Wang S 2017 Wang Z 2015 Yang 2014 Subtotal (65% CI) Heterogeneity: Tau Test for overall effe 14.2 Landioloi Kaikinana 2020 Whitehouse 2023 Subtotal (65% CI) Heterogeneity: Tau Test for overall effe Test for overall effe 1.5.1 Esmoloi Cocchi 2022 Morelli 2013 Subtotal (95% CI) Heterogeneity: Chi Test for overall effe 1.5.2 Landioloi Kakihana 2020 Whitehouse 2023 Subtotal (95% CI) Heterogeneity: Chi Test for overall effe Total (95% CI) Heterogeneity: Chi Test for overall effe Total (95% CI)		Total Mean	n SD 6 1.6 9 4.9 2 12.64 7 12.2 9 7.3 20): I ² = 1 8 15.4 6 0.5 0.02): I ² = 1 0.030; I ² = 1 0.030; I ² = 2 0.030; I ² = 2 0.5 5 5 5 5 5 5 5 5 5 5 5	Total 244 277 50 300 200 231 231 138 30% 3699 38% = 0% 369 775 50 300% 369 387% = 0% Total V 77 50 30 179 75 63 138 3137 1	Weight 8.2% 17.6% 13.9% 9.8% 9.8% 9.8% 9.8% 7.4% 67.0% 17.3% 17.3% 67.0% 17.3%	IV. Random. 95% (-0.52 [-1.10, 0.06 -0.02 [-0.34, 0.29] -0.16 [-0.23, 0.55 -0.41 [-0.22, 0.15 -0.41, 0.60 -0.25 [-0.66, 0.37 -0.10 [-0.31, 0.11 -0.39 [-0.75, -0.46 -0.39 [-0.75, -0.46 -0.11 [-0.30, 0.08 -0.11 [-0.30, 0.08 -0.11 [-0.30, 0.08 -0.13 [-0.33, 0.08] 0.33 [0.00, 0.655] 0.34 [0.10, 0.57] 0.08 [-0.08, 0.23]	2 IV. Rands	Dimensional and the second se	 Mean Arterial Pressure at 24h, mmHg Norepinephrine dose at 24h, μg/kg/mi

assessment, with the assessment being inconclusive for the remaining four studies (Yang et al., 2014; Liu et al., 2015; Wang et al., 2017; Wang et al., 2023) due to inadequate information. In terms of other biases, four studies (Yang et al., 2014; Kakihana et al., 2020; Cocchi et al., 2022; Whitehouse

et al., 2023) were conducted at multiple centers and considered low risk, while the remaining six studies (Morelli et al., 2013; Liu et al., 2015; Wang et al., 2015; Wang et al., 2017; Liu et al., 2019; Wang et al., 2023) conducted at a single center were deemed high risk.



variance; Std., standardized

Primary outcome

A total of 8 (Morelli et al., 2013; Liu et al., 2015; Wang et al., 2015; Wang et al., 2017; Liu et al., 2019; Kakihana et al., 2020; Wang et al., 2023; Whitehouse et al., 2023) out of 10 RCTs with 797 participants reported 28-day mortality outcomes. The results indicated that administering ultrashort-acting βblockers (esmolol/landiolol) to patients with sepsis who had persistent tachycardia despite initial resuscitation was significantly associated with a lower 28-day mortality rate (RR: 0.73; 95% CI: 0.57–0.93; and *p* < 0.01). Notably, subgroup analysis revealed differing outcomes. The use of esmolol in sepsis patients was significantly linked to reduced 28-day mortality (RR: 0.68; 95% CI: 0.55–0.84; and *p* < 0.001), whereas there was no significant difference between the landiolol and control groups (RR: 0.98; 95% CI: 0.41-2.34; and p = 0.96) (see Figure 2). The funnel plot is shown in Supplementary Figure S3.

Secondary outcomes

The study evaluated secondary outcomes including 90-day mortality (Figure 3A), heart rate (Figure 3B), mean arterial

pressure (Figure 3C), norepinephrine dose (Figure 3D), lactate levels (Figure 4A), cardiac index (Figure 4B), stroke volume index (Figure 4C), and troponin I levels (Figure 4D) at 24 h after enrollment, and length of stay in the ICU (Figure 5).

Four studies (Morelli et al., 2013; Kakihana et al., 2020; Wang et al., 2023; Whitehouse et al., 2023) examined adverse events, with one (Morelli et al., 2013) showing no adverse events in either group and another reporting asymptomatic bradycardia in the experimental group but no significant arrhythmias in the control group. The remaining two studies (Kakihana et al., 2020; Whitehouse et al., 2023) reported adverse events in both the landiolol and control groups. One study (Kakihana et al., 2020) reported that adverse events were observed in 9 (12%) of the 77 patients in the landiolol group and 8 (11%) of the 74 patients in the control group. Another study (Whitehouse et al., 2023) reported that adverse events were observed in 17.5% (10/63) of those receiving landiolol and 12.7% (8/ 63) of those receiving standard care.

Trial sequential analysis

The TSA results are shown in Figure 6. A total of 6 clinical trials (Morelli et al., 2013; Liu et al., 2015; Wang et al., 2015;

	Esmol	ol/Landi	iolol	C	ontrol		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.10.1 Esmolol									
Cocchi 2022	8.15	3.02	18	6.42	2.36	22	14.9%	0.63 [-0.01, 1.27]	
Liu H 2019	7.07	1.95	50	5.39	1.89	50	16.7%	0.87 [0.46, 1.28]	-
Morelli 2013	19.4	2.07	77	14.26	3.74	77	17.0%	1.69 [1.32, 2.06]	-
Wang J 2023	10.96	7.99	50	11.62	5.99	50	16.9%	-0.09 [-0.48, 0.30]	
Subtotal (95% CI)			195			199	65.6%	0.78 [-0.04, 1.60]	◆
Heterogeneity: Tau ² =	0.64: Chi ²	= 42.58	. df = 3	(P < 0.0	00001)	; l ² = 9;	3%		
Test for overall effect:	Z = 1.87 (P = 0.06)	,	,				
1.10.2 Landiolol									
Kakihana 2020	14.6	8.6	69	13.3	9.1	72	17.3%	0.15 [-0.18, 0.48]	
Whitehouse 2023	21.3	31.7	63	19.6	19.3	63	17.2%	0.06 [-0.28, 0.41]	
Subtotal (95% CI)			132			135	34.4%	0.11 [-0.13, 0.35]	•
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.11,	df = 1 (P = 0.74	1); ² =	0%			
Test for overall effect:	Z = 0.88 (P = 0.38)						
root for oronal onoot.									
			007			334	100.0%	0.55 [-0.02, 1.12]	•
Total (95% CI)			327					L / /	+
Total (95% CI) Heterogeneity: Tau ² =	0.46; Chi ²	= 62.39	327 , df = 5	(P < 0.0	00001)	; l ² = 9:	2%		
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect:	0.46; Chi² Z = 1.88 (= 62.39 P = 0.06	327 , df = 5	(P < 0.0	00001)	; l ² = 9:	2%		

FIGURE 5

Forest plot of esmolol or landiolol group vs. control group: LOS in ICU. LOS, length of stay; ICU, intensive care unit; IV, inverse variance; Std., standardized.



Wang et al., 2017; Liu et al., 2019; Wang et al., 2023) involving 522 patients were included in the esmolol subgroup metaanalysis, with an actual sample size of 586 cases. The TSA results indicated that the cumulative Z-curve crossed both the traditional and TSA boundary values simultaneously, leading to a positive conclusion being reached before the expected sample size. This suggests that for patients with sepsis who continue to experience tachycardia after initial fluid resuscitation, esmolol provides a 28-day survival advantage with accurate evidence.

Outcome	Subgroup	No. of studies	No. of participants	Effect size (95% CI)	p
28-day mortality	Total	8	797	RR, 0.73 (0.57, 0.93)	0.009
	Esmolol	6	522	RR, 0.68 (0.55, 0.84)	0.0003
	Landiolol	2	275	RR, 0.98 (0.41, 2.34)	0.96
90-day mortality	Total	3	325	RR, 0.99 (0.72, 1.35)	0.93
	Esmolol	2	200	RR, 0.87 (0.71, 1.05)	0.15
	Landiolol	1	125	RR, 1.52 (0.94, 2.47)	0.09
HR at 24 h	Total	9	839	SMD, -1.65 (-2.38, -0.91)	°0.0001
	Esmolol	7	563	SMD, -2.04 (-2.94, -1.13)	^{<} 0.0001
	Landiolol	2	276	SMD, -0.39 (-0.67, -0.11)	0.006
MAP at 24 h	Total	8	739	SMD, -0.11 (-0.30, 0.08)	0.26
	Esmolol	6	463	SMD, -0.10 (-0.31, 0.11)	0.34
	Landiolol	2	276	SMD, -0.11 (-0.65, 0.42)	0.67
NE dose at 24 h	Total	6	630	SMD, 0.88 (-0.08, 0.23)	0.34
	Esmolol	4	354	SMD, -0.13 (-0.33, 0.08)	0.24
	Landiolol	2	276	SMD, 0.34 (0.10, 0.57)	0.006
Lac at 24 h	N/A	7	503	SMD, -0.03 (-0.98, 0.91)	0.95
CI at 24 h	N/A	6	463	SMD, -0.09 (-0.49, 0.32)	0.68
SVI at 24 h	N/A	5	363	SMD, 0.27 (0.07, 0.48)	0.01
TnI at 24 h	N/A	2	101	SMD, -0.58 (-0.98, -0.18)	0.004
LOS in ICU	Total	6	661	SMD, 0.55 (-0.02, 1.12)	0.06
	Esmolol	4	394	SMD, 0.78 (-0.04, 1.60)	0.06
	Landiolol	2	267	SMD, 0.11 (-0.13, 0.35)	0.38

TABLE 2 Summary of meta-analysis.

Note: HR, heart rate; MAP, mean arterial pressure; NE, norepinephrine; Lac, lactate; CI, cardiac index; SVI, stroke volume index; RR, relative risks; SMD, standard mean difference.

Discussion

The meta-analysis revealed that the use of ultrashort-acting β blockers (esmolol/landiolol) in septic patients with persistent tachycardia post-resuscitation was linked to reduced 28-day mortality. Subgroup analysis indicated esmolol as the preferred choice for these patients, while the limited sample size prevented the identification of survival benefits with landiolol. This study addresses existing controversies and offers valuable insights for clinical decision-making. The summary of meta-analysis was shown in Table 2.

According to the Surviving Sepsis Guideline (Evans et al., 2021), norepinephrine is recommended as a first-line drug for treating septic shock to maintain stable hemodynamics. However, it is well-recognized that norepinephrine use can elevate catecholamine levels, potentially leading to cardiac dysfunction due to sympathetic hyperstimulation (Monnet et al., 2011; Jozwiak, 2022). Studies (Havaldar, 2018; Prescott Hallie and Angus Derek, 2018) have highlighted that cardiac dysfunction plays a crucial role in the poor prognosis of septic patients, with tachycardia increasing cardiac workload and myocardial oxygen consumption,

contributing to cardiac dysfunction (Lanspa et al., 2017; Suzuki et al., 2017). Recent research studies have indicated that reducing the heart rate of septic patients to a specific level, alongside adequate fluid resuscitation and circulatory stability, can effectively enhance patient outcomes. A randomized openlabel clinical trial conducted by Morelli et al. (2013) and published in JAMA in 2013 yielded positive results. The study demonstrated that all patients in the esmolol group achieved the target heart rate, with a higher cardiac stroke volume index than that in the control group, aligning with our study's findings.

The traditional belief that β -blockers are unsuitable for patients with sepsis/septic shock due to their cardiac suppressive effects is being challenged. This study compared the effects of esmolol and landiolol on the mean arterial pressure, showing no significant difference compared to the control group. However, the landiolol group may require a higher dose of norepinephrine to maintain a relatively stable mean arterial pressure. Both esmolol and landiolol, as selective β 1-blockers with a rapid onset of action, require dose titration for optimal bradycardic effects. Landiolol is also approved for treating ventricular fibrillation or tachycardia (Sakamoto et al.,

10.3389/fphar.2024.1380175

2012; Nagai et al., 2013; Taenaka and Kikawa, 2013). Evidence from case reports, retrospective studies, and animal research supports the use of landiolol for sepsis-related tachyarrhythmias (Okajima et al., 2015; Mathieu et al., 2018; Gangl et al., 2022). Two clinical trials (Kakihana et al., 2020; Whitehouse et al., 2023) specifically evaluated the efficacy of landiolol in sepsis treatment. The J-land 3S study (Kakihana et al., 2020) showed a higher proportion of patients achieving target heart rates in the landiolol group than in the control group, with a significant reduction in new arrhythmias. The results showed that a total of 41 patients (55%) in the landiolol group had a heart rate of 60-94 beats/min 24 h after enrollment, while only 25 patients (33%) in the control group showed the same. There was a statistical difference between the two groups (p = 0.0031), and the incidence of new arrhythmias within 7 days was significantly reduced (9% vs. 25%, p = 0.015). However, the 28-day mortality rates did not significantly differ between the landiolol and control groups. Another clinical study (Whitehouse et al., 2023) published in JAMA in 2023 (STRESS-L) did not support the use of landiolol in sepsis. The result showed that there was no statistically significant difference between the average SOFA score of the landiolol group (8.8 ± 3.9) and that of the control group (8.1 ± 3.2) (*p* = 0.24). In addition, the 28-day mortality (37.1%) and 90-day mortality (43.5%) rates in the landiolol group were higher than those in the control group (25.4% and 14.9%), but there was no statistical difference between the groups (p > 0.05). More importantly, the incidence of serious adverse events in the landiolol group (25.4%) was significantly higher than that of the control group (6.4%), with a statistical difference between the groups (p = 0.006).

A previous meta-analysis (Hasegawa et al., 2021) examined the impact of β -blockers on the mortality of patients with sepsis and tachycardia. Our study differs from this previous analysis by conducting a subgroup analysis specifically focusing on the effects of esmolol and landiolol on the mortality of patients with sepsis and tachycardia. Our findings indicate that esmolol significantly reduces the 28-day mortality rate in these patients, whereas landiolol does not show the same effect. Furthermore, the study reveals that landiolol necessitated an increased dose of norepinephrine to maintain mean arterial pressure, suggesting an indirect impact on the hemodynamics of patients with sepsis and tachycardia. Therefore, our study advocates for the use of esmolol in treating patients with septic tachycardia, aligning with findings from previous research. However, the limited sample size prevented the identification of survival benefits with landiolol.

Conclusion

The meta-analysis indicated that the use of esmolol in patients with persistent tachycardia, despite initial resuscitation, was linked to a notable reduction in 28-day mortality rates. Therefore, this study

References

Cocchi, M. N., Dargin, J., Chase, M., Patel, P. V., Grossestreuer, A., Balaji, L., et al. (2022). Esmolol to treat the hemodynamic effects of septic shock: a randomized controlled trial. *Shock* 57, 508–517. doi:10.1097/SHK.000000000001905

advocates for the consideration of esmolol in the treatment of sepsis in cases where tachycardia persists despite initial resuscitation.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Author contributions

PH: data curation, formal analysis, software, writing-original draft, and writing-review and editing. FL: data curation and writing-review and editing. XH: data curation and writing-review and editing. BL: methodology, software, and writing-review and editing. XX: supervision and writing-review and editing. QL: funding acquisition, supervision, validation, visualization, and writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The present study was supported by the National Natural Science Foundation of China (No. 82205070).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2024.1380175/ full#supplementary-material

Evans, L., Rhodes, A., Waleed, A., Antonelli, M., Coopersmith, C. M., French, C., et al. (2021). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* 47, 1181–1247. doi:10.1007/s00134-021-06506-y

Gangl, C., Krychtiuk Konstantin, A., Schoenbauer, R., and Speidl, W. S. (2022). Landiolol for refractory tachyarrhythmias in the intensive care unit: case reports. *Eur. Heart J. Suppl.* 24, D43–D49. doi:10.1093/eurheartjsupp/suac026

Hasegawa, D., Ryota, S., Narut, P., Nishida, K., Takahashi, K., Yatabe, T., et al. (2021). Effect of ultrashort-acting β -blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation: a systematic review and meta-analysis of randomized controlled trials. *Chest* 159, 2289–2300. doi:10.1016/j.chest.2021.01.009

Havaldar, A. A. (2018). Evaluation of sepsis induced cardiac dysfunction as a predictor of mortality. *Cardiovasc Ultrasound* 16, 31. doi:10.1186/s12947-018-0149-4

Hayase, N., Yamamoto, M., Asada, T., Isshiki, R., Yahagi, N., and Doi, K. (2016). Association of heart rate with N-terminal pro-B-type natriuretic peptide in septic patients: a prospective observational cohort study. *Shock* 46, 642–648. doi:10.1097/SHK. 0000000000000673

Hollenberg Steven, M. (2023). β -Blockers in patients with sepsis: putting the puzzle together, piece by piece. JAMA 330, 1627–1628. doi:10.1001/jama.2023.20455

Huang, P., Zheng, X., Liu, Z., and Fang, X. (2021). The efficacy and safety of esmolol for septic shock: a systematic review and meta-analysis of randomized controlled trials. *Front. Pharmacol.* 12, 682232. doi:10.3389/fphar.2021.682232

Jozwiak, M. (2022). Alternatives to norepinephrine in septic shock: which agents and when? J. Intensive Med. 2, 223–232. doi:10.1016/j.jointm.2022.05.001

Kakihana, Y., Nishida, O., Takumi, T., Okajima, M., Morimatsu, H., Ogura, H., et al. (2020). Efficacy and safety of landiolol, an ultra-short-acting β 1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. *Lancet Respir. Med.* 8, 863–872. doi:10.1016/S2213-2600(20)30037-0

Kuipers, S., Klein Klouwenberg, P. M., and Cremer, O. L. (2014). Incidence, risk factors and outcomes of new-onset atrial fibrillation in patients with sepsis: a systematic review. *Crit. Care* 18, 688. doi:10.1186/s13054-014-0688-5

Lall, R., Dipesh, M., Emma, S., Boota, N., Regan, S., Bion, J., et al. (2021). Study into the reversal of septic shock with landiolol (beta blockade): STRESS-L Study protocol for a randomised trial. *BMJ Open* 11, e043194. doi:10.1136/bmjopen-2020-043194

Lanspa, M. J., Sajid, S., Andrew, H., Wilson, E. L., Olsen, T. D., Hirshberg, E. L., et al. (2017). Associations among left ventricular systolic function, tachycardia, and cardiac preload in septic patients. *Ann. Intensive Care* 7, 17. doi:10.1186/s13613-017-0240-2

Li, A., Lowell, L., Hanyu, Q., Arabi, Y. M., Myatra, S. N., Egi, M., et al. (2022). Epidemiology, management, and outcomes of sepsis in ICUs among countries of differing national wealth across asia. *Am. J. Respir. Crit. Care Med.* 206, 1107–1116. doi:10.1164/rccm.202112-2743OC

Liu, H., Ding, X. F., Zhang, S. G., Wang, H. X., Luo, Y. G., Duan, X. G., et al. (2019). Effect of esmolol in septic shock patients with tachycardia: a randomized clinical trial. *Zhonghua Yi Xue Za Zhi* 99 (17), 1317–1322. doi:10.3760/cma.j.issn.0376-2491.2019. 17.009

Liu, P., Qi, W., Tang, Y., Zhou, Z., and Feng, M. (2018). The influence of esmolol on septic shock and sepsis: a meta-analysis of randomized controlled studies. *Am. J. Emerg. Med.* 36, 470–474. doi:10.1016/j.ajem.2017.11.013

Liu, X., Huang, W., Wen, M., Wenxin, Z., Wenqiang, J., Shenglong, C., et al. (2015). Esmolol improves clinical outcome and tissue oxygen metabolism in patients with septic shock through controlling heart rate. *Chin. Crit. Care Med.* 27 (9), 759–763.

Mathieu, C., Martine, D., Frank, K., Lalevée, N., Lan, C., Fourny, N., et al. (2018). Sex-mediated response to the beta-blocker landiolol in sepsis: an experimental, randomized study. *Crit. Care Med.* 46, e684–e691. doi:10.1097/CCM. 000000000003146

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., and PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann. Intern Med.* 151 (4), 264–W64. doi:10.7326/0003-4819-151-4-200908180-00135

Monnet, X., Julien, J., Julien, M., Richard, C., and Teboul, J. L. (2011). Norepinephrine increases cardiac preload and reduces preload dependency assessed by passive leg raising in septic shock patients. *Crit. Care Med.* 39, 689–694. doi:10.1097/CCM. 0b013e318206d2a3

Morelli, A., Ertmer, C., Westphal, M., Rehberg, S., Kampmeier, T., Ligges, S., et al. (2013). Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. *JAMA* 310 (16), 1683–1691. doi:10.1001/jama.2013.278477

Nagai, R., Kinugawa, K., Inoue, H., Atarashi, H., Seino, Y., Yamashita, T., et al. (2013). Urgent management of rapid heart rate in patients with atrial fibrillation/ flutter and left ventricular dysfunction: comparison of the ultra-short-acting β 1selective blocker landiolol with digoxin (J-Land Study). *Circ. J.* 77, 908–916. doi:10. 1253/circj.cj-12-1618

Okajima, M., Masayuki, T., and Takumi, T. (2015). Landiolol, an ultra-short-acting β 1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J. Crit. Care Med. 4, 251–257. doi:10.5492/wjccm.v4.i3.251

Parker, M. M., Shelhamer, J. H., Natanson, C., Alling, D. W., and Parrillo, J. E. (1987). Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. *Crit. Care Med.* 15, 923–929. doi:10.1097/ 00003246-198710000-00006

Prescott Hallie, C., and Angus Derek, C. (2018). Enhancing recovery from sepsis: a review. JAMA 319, 62-75. doi:10.1001/jama.2017.17687

Sakamoto, A., Kitakaze, M., Takamoto, S., Namiki, A., Kasanuki, H., Hosoda, S., et al. (2012). Landiolol, an ultra-short-acting β_1 -blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study). Circ. J. 76, 1097–1101. doi:10. 1253/circj.cj-11-1332

Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315, 801–810. doi:10.1001/jama.2016.0287

Suzuki, T., Suzuki, Y., Jun, O., Kurazumi, T., Suhara, T., Ueda, T., et al. (2017). Sepsisinduced cardiac dysfunction and β -adrenergic blockade therapy for sepsis. *J. Intensive Care* 5, 22. doi:10.1186/s40560-017-0215-2

Taenaka, N., and Kikawa, S. (2013). The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β 1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study. Am. J. Cardiovasc Drugs 13, 353–364. doi:10.1007/s40256-013-0035-2

Walkey, A. J., Hammill, B. G., Curtis, L. H., and Benjamin, E. J. (2014). Long-term outcomes following development of new-onset atrial fibrillation during sepsis. *Chest* 146, 1187–1195. doi:10.1378/chest.14-0003

Wang, J., Gao, X., He, Z., Xu, G., and Li, T. (2023). Evaluating the effects of Esmolol on cardiac function in patients with Septic cardiomyopathy by Speck-tracking echocardiography-a randomized controlled trial. *BMC Anesthesiol.* 23, 51. doi:10. 1186/s12871-023-01983-8

Wang, S., Li, M., Duan, J., Yi, L., Huang, X., Chen, D., et al. (2017). Effect of esmolol on hemodynamics and clinical outcomes in patients with septic shock. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 29 (5), 390–395. doi:10.3760/cma.j.issn. 2095-4352.2017.05.002

Wang, Z., Wu, Q., Nie, X., Guo, J., and Yang, C. (2015). Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. *Clin. Drug Investig.* 35 (11), 707–716. doi:10.1007/ s40261-015-0325-3

Weng, L., Yang, X., Peng, Y., Wang, Y., Chen, Y., Liu, W., et al. (2023). National incidence and mortality of hospitalized sepsis in China. *Crit. Care* 27, 84. doi:10.1186/s13054-023-04385-x

Whitehouse, T., Hossain, A., Perkins Gavin, D., Gordon, A. C., Bion, J., Young, D., et al. (2023). Landiolol and organ failure in patients with septic shock: the STRESS-L randomized clinical trial. *JAMA* 330, 1641–1652. doi:10.1001/jama. 2023.20134

Yang, Q., Kong, T., Ziping, B., Yang, S., Chen, X., Zheng, J., et al. (2023). Association between the β-blocker use and patients with sepsis: a cohort study. *Front. Med.* (*Lausanne*) 10, 1272871. doi:10.3389/fmed.2023.1272871

Yang, S., Liu, Z., Yang, W., Zhang, G., Hou, B., Liu, J., et al. (2014). Effects of the β blockers on cardiac protection and hemodynamics in patients with septic shock: a prospective study. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 26 (10), 714–717. doi:10. 3760/cma.j.issn.2095-4352.2014.10.007